김범준 교수
전문진료분야
소화기암 (대장암, 간담도췌장암, 식도암, 위암 등), 두경부암, 양성혈액질환(빈혈, 혈소판, 백혈구 질환)
전화 예약
1577-1801
기본정보
학력
2018.03 ~ 2020.02한림대학교 의과대학 박사 2013.09 ~ 2017.02한림대학교 의과대학 석사 2004.03 ~ 2010.02한림대학교 의과대학 학사 |
경력
2024.07 ~ (현) 한림대학교성심병원 공공의료본부 본부장 2026.03 ~ (현) 한림대학교성심병원 종양-혈액내과 부교수 2026.06 ~ 2026.02온케어 보호자 화상 회진 시스템 개발 2020.05 ~ 2026.02한림대학교성심병원 종양-혈액내과 조교수 2017.03 ~ 2020.04국군수도병원 혈액종양내과 중견의 2016.03 ~ 2017.02한림대학교 강남성심병원 혈액종양내과 전임의 2015.03 ~ 2016.02서울아산병원 종양내과 전임의 2011.03 ~ 2015.02한림대학교성심병원 내과 전공의 2010.03 ~ 2011.02 한림대학교성심병원 인턴 |
학회활동
대한암학회 정회원 대한항암요법연구회 정회원 한국임상암학회 정회원 대한내과학회 정회원 대한혈액학회 정회원 |
논문
주저자 (제1저자 또는 교신저자) 논문
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). Gastric Cancer (2022)
A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer. J Cancer (2022)
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16). Ther Adv Med Oncol (2021)
The efficacy and safety of onartuzumab in patients with solid cancer: A meta-analysis of randomized trials. Indian J Cancer (2021)
Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification. Invest New Drugs (2020)
Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin. Cancer Res Treat (2019)
Helicobacter pylori Eradication in Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of Randomized Trials. Gastroenterol Res Pract (2018)
A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine. Cancer Res Treat (2017)
Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer (2017)
Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen. Cancer Res Treat (2017)
Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol (2017)
Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review. Oncotarget (2017)
Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review. Oncotarget (2017)
Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review. Oncotarget (2017)
The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis. Oncotarget (2017)
Moderate to Severe Thrombocytopenia During Pregnancy: A Single Institutional Experience. Indian J Hematol Blood Transfus (2017)
The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review. Oncotarget (2017)
Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. J Cancer (2017)
The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: a meta-analysis of randomized trials. Oncotarget (2017)
KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review. Oncotarget (2016)
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). Gastric Cancer (2022)
A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer. J Cancer (2022)
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16). Ther Adv Med Oncol (2021)
The efficacy and safety of onartuzumab in patients with solid cancer: A meta-analysis of randomized trials. Indian J Cancer (2021)
Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification. Invest New Drugs (2020)
Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin. Cancer Res Treat (2019)
Helicobacter pylori Eradication in Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of Randomized Trials. Gastroenterol Res Pract (2018)
A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine. Cancer Res Treat (2017)
Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer (2017)
Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen. Cancer Res Treat (2017)
Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol (2017)
Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review. Oncotarget (2017)
Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review. Oncotarget (2017)
Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review. Oncotarget (2017)
The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis. Oncotarget (2017)
Moderate to Severe Thrombocytopenia During Pregnancy: A Single Institutional Experience. Indian J Hematol Blood Transfus (2017)
The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review. Oncotarget (2017)
Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. J Cancer (2017)
The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: a meta-analysis of randomized trials. Oncotarget (2017)
KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review. Oncotarget (2016)